keyword
MENU ▼
Read by QxMD icon Read
search

Tenofovir

keyword
https://www.readbyqxmd.com/read/28531309/effect-of-antiretroviral-therapy-on-bone-and-renal-health-in-young-adults-infected-with-hiv-in-early-life
#1
Aylin B Unsal, Aviva S Mattingly, Sara E Jones, Julia B Purdy, James C Reynolds, Jeffrey B Kopp, Rohan Hazra, Colleen M Hadigan
Context: HIV antiretroviral (ARV) therapy is associated with renal and bone toxicity, but little is known about the potential cumulative effects in adults exposed to ARVs from birth. Objective: To prospectively evaluate renal and bone health in young adults with lifelong HIV and extensive ARV exposure. Design: Cross-sectional comparison of bone mineral density (BMD by dual-energy X-ray absorptiometry), bone turnover and renal function in young adults infected with HIV in early life (n=65) to matched healthy controls (n=23) and longitudinal evaluation (mean follow-up 4...
May 22, 2017: Journal of Clinical Endocrinology and Metabolism
https://www.readbyqxmd.com/read/28528404/a-direct-comparison-of-the-effects-of-the-antiretroviral-drugs-stavudine-tenofovir-and-the-combination-lopinavir-ritonavir-on-bone-metabolism-in-a-rat-model
#2
M M Conradie, M van de Vyver, E Andrag, M Conradie, W F Ferris
Antiretroviral (ARV) treatment may induce metabolic complications in HIV patients on long-term therapy that can affect bone health. In this study, the effects of the ARVs Stavudine (d4T), Tenofovir (TDF) and Lopinavir/ritonavir (LPV/r) on bone metabolism and lipodystrophy were directly compared in rats to negate the consequences of HIV-associated confounding factors. Healthy 12-14-week-old male Wistar rats (n = 40) were divided into four treatment groups and received an oral animal equivalent dose of either Stavudine (6...
May 20, 2017: Calcified Tissue International
https://www.readbyqxmd.com/read/28522769/osteoporosis-and-osteopenia-are-not-associated-with-t-cell-activation-in-older-cart-treated-hiv-infected-patients
#3
M Krikke, R C W Klomberg, E van der Veer, K Tesselaar, H J J Verhaar, A I M Hoepelman, J E Arends
BACKGROUND: A higher risk of developing osteopenia/ osteoporosis has been seen in HIV-infected patients. We compared HIV-infected patients, all treated with combination antiretroviral therapy (cART), with a low bone mineral density (BMD) (T-score < -1) to those with a normal BMD (T-score > -1), examining the relation with T-cell activation and bone turnover markers (c-terminal telopeptide (CTX) and procollagen type 1 amino-terminal propeptide (P1NP)). METHODS: In this single visit pilot study, bone turnover markers, T-cell activation (CD38 + HLA - DR +) and senescence (CD57+) of T cells were measured in patients who had previously undergone dual energy X-ray absorptiometry scanning...
May 2017: Netherlands Journal of Medicine
https://www.readbyqxmd.com/read/28522204/peg-interferon-plus-nucleotide-analogue-treatment-versus-no-treatment-in-patients-with-chronic-hepatitis-b-with-a-low-viral-load-a-randomised-controlled-open-label-trial
#4
Annikki de Niet, Louis Jansen, Femke Stelma, Sophie B Willemse, Sjoerd D Kuiken, Sebastiaan Weijer, Carin M J van Nieuwkerk, Hans L Zaaijer, Richard Molenkamp, R Bart Takkenberg, Maarten Koot, Joanne Verheij, Ulrich Beuers, Hendrik W Reesink
BACKGROUND: Antiviral treatment is currently not recommended for patients with chronic hepatitis B with a low viral load. However, they might benefit from acquiring a functional cure (hepatitis B surface antigen [HBsAg] loss with or without formation of antibodies against hepatitis B surface antigen [anti-HBs]). We assessed HBsAg loss during peg-interferon-alfa-2a (peg-IFN) and nucleotide analogue combination therapy in patients with chronic hepatitis B with a low viral load. METHODS: In this randomised controlled, open-label trial, patients were enrolled from the Academic Medical Center (AMC), Amsterdam, Netherlands...
May 15, 2017: Lancet. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28521532/new-antivirals-for-the-treatment-of-chronic-hepatitis-b
#5
Vincent Soriano, Pablo Barreiro, Laura Benitez, Jose M Peña, Carmen de Mendoza
Current treatment with oral nucleos(t)ides entecavir or tenofovir provide sustained suppression of HBV replication and clinical benefit in most chronic hepatitis B virus (HBV) infected persons. However, HBV rebound generally occurs upon drug discontinuation due to persistence of genomic HBV reservoirs as episomic cccDNA and chromosomic integrated HBV-DNA. There is renewed enthusiasm on HBV drug discovery following recent successes with antivirals for hepatitis C and immunotherapies for some cancers. Areas covered: New drugs that target distinct steps of the HBV life cycle are been developed, including inhibitors of viral entry, new polymerase inhibitors, capsid and assembly inhibitors, virus release blockers, and disruptors of cccDNA formation and transcription...
May 18, 2017: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/28520146/association-of-tenofovir-disoproxil-fumarate-with-primary-allograft-survival-in-hiv-positive-kidney-transplant-recipients
#6
Suzanne M Boyle, Gregory Malat, Meera N Harhay, Dong H Lee, Lisa Pang, Sindhura Talluri, Akshay Sharma, Tiffany E Bias, Karthik Ranganna, Alden M Doyle
BACKGROUND: Tenofovir disoproxil fumarate (TDF) is an anti-retroviral agent frequently used to treat human immunodeficiency virus (HIV). There are concerns regarding its potential to cause acute kidney injury, chronic kidney disease, and proximal tubulopathy. Although TDF can effectively suppress HIV after kidney transplantation, it is unknown whether use of TDF-based anti-retroviral therapy (ART) after kidney transplant (KT) adversely affects allograft survival. METHODS: We examined 104 HIV+ KT recipients at our center between 2001 and 2014...
May 18, 2017: Transplant Infectious Disease: An Official Journal of the Transplantation Society
https://www.readbyqxmd.com/read/28511283/a-different-inhibitor-is-required-for-overcoming-entecavir-resistance-a-comparison-of-four-rescue-therapies-in-a-retrospective-study
#7
Guosheng Yuan, Chengguang Hu, Yuchen Zhou, Junwei Liu, Huaping Huang, Yuan Li, Dinghua Yang, Fuyuan Zhou, Yong-Yuan Zhang, Yuanping Zhou
AIMS: Little clinical data are available regarding reestablishing the effective inhibition of entecavir (ETV)-resistant mutants. In this retrospective study, we aimed to compare the efficacies of four treatment regimens as rescue therapy for those chronic hepatitis B (CHB) patients with ETV resistance. METHODS: A total of 65 patients with ETV resistance were assigned either with tenofovir disoproxil fumarate (TDF) monotherapy (n=21), ETV (0.5 mg) plus adefovir (ADV) combination therapy (n=19), ETV (1...
May 16, 2017: British Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/28505168/development-and-validation-of-reversed-phase-hplc-gradient-method-for-the-estimation-of-efavirenz-in-plasma
#8
Shweta Gupta, Rajesh Kesarla, Narendra Chotai, Abdelwahab Omri
Efavirenz is an anti-viral agent of non-nucleoside reverse transcriptase inhibitor category used as a part of highly active retroviral therapy for the treatment of infections of human immune deficiency virus type-1. A simple, sensitive and rapid reversed-phase high performance liquid chromatographic gradient method was developed and validated for the determination of efavirenz in plasma. The method was developed with high performance liquid chromatography using Waters X-Terra Shield, RP18 50 x 4.6 mm, 3.5 μm column and a mobile phase consisting of phosphate buffer pH 3...
2017: PloS One
https://www.readbyqxmd.com/read/28504780/is-tenofovir-the-answer-to-further-preventing-mother-to-child-transmission-of-hepatitis-b
#9
M I Abdul Hafidz, S-S Tan, Y Y Lee
No abstract text is available yet for this article.
December 2016: Journal of the Royal College of Physicians of Edinburgh
https://www.readbyqxmd.com/read/28503983/design-and-in-vitro-evaluation-of-tenofovir-loaded-vaginal-gels-for-the-prevention-of-hiv-infections
#10
Selin Seda Timur, Adem Şahin, Eren Aytekin, Naile Öztürk, Kerem Heybet Polat, Nurten Tezel, Reyhan Neslihan Gürsoy, Sema Çalış
Infection with the human immunodeficiency virus (HIV) is affecting women disproportionally with increasing incidence rates over the last decades. Tenofovir is one of the most commonly used antiretroviral agents, which belongs to the nucleoside/nucleotide reverse transcriptase inhibitor family, for the prevention of HIV acquisition. In scope of this study, a thermogelling system containing tenofovir - loaded chitosan nanoparticles for the controlled release of tenofovir was developed and characterized. The in vitro release studies have shown that the burst release effect was decreased to 27% with f-TFV CS NPs-Gel...
May 15, 2017: Pharmaceutical Development and Technology
https://www.readbyqxmd.com/read/28502443/hepatitis-b-and-c
#11
REVIEW
Wikrom Karnsakul, Kathleen B Schwarz
Chronic viral hepatitis is a global health threat and financial burden. Hepatitis B and C viruses (HBV and HCV) are the most common causes of chronic viral hepatitis in the United States. Most cases are asymptomatic before adulthood. Research has resulted in effective therapy for HCV and the promise of effective therapies for HBV. For HCV, therapy is pegylated interferon and ribavirin. Clinical trials with effective direct-acting antiviral agents are underway in pediatrics. For HBV, approved agents are alpha-interferon, lamivudine, adefovir, tenofovir, and entecavir...
June 2017: Pediatric Clinics of North America
https://www.readbyqxmd.com/read/28498892/incident-aids-or-death-after-initiation-of-human-immunodeficiency-virus-treatment-regimens-including-raltegravir-or-efavirenz-among-adults-in-the-united-states
#12
Stephen R Cole, Jessie K Edwards, H Irene Hall, M Alan Brookhart, W Christopher Mathews, Richard D Moore, Heidi M Crane, Mari M Kitahata, Michael J Mugavero, Michael S Saag, Joseph J Eron
Background.: The long-term effectiveness of human immunodeficiency virus (HIV) treatments containing integrase inhibitors is unknown. Methods.: We use observational data from the Centers for AIDS Research Network of Integrated Clinical Systems and the Centers for Disease Control and Prevention to estimate 4-year risk of AIDS and all-cause mortality among 415 patients starting a raltegravir regimen compared to 2646 starting an efavirenz regimen (both regimens include emtricitabine and tenofovir disoproxil fumarate)...
June 1, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/28493172/tenofovir-alafenamide-a-review-in-chronic-hepatitis-b
#13
Lesley J Scott, Henry L Y Chan
Tenofovir alafenamide (AF) [Vemlidy(®)], an oral prodrug of tenofovir, was developed to optimize the antiviral potency and clinical safety of the active moiety tenofovir diphosphate (selective reverse transcriptase nucleotide inhibitor). In two identically designed, ongoing, multinational trials in treatment-naive and -experienced adult patients with hepatitis B e antigen (HBeAg)-positive or -negative chronic hepatitis B virus (HBV) infection, once-daily tenofovir AF 25 mg provided effective and sustained viral suppression (120-week analysis), and was generally well tolerated...
June 2017: Drugs
https://www.readbyqxmd.com/read/28492396/preexposure-prophylaxis-failure-with-tenofovir-disoproxil
#14
Stefan Esser, Hendrik Streeck
No abstract text is available yet for this article.
June 1, 2017: AIDS
https://www.readbyqxmd.com/read/28492395/hiv-prevention-response-to-pre-exposure-prophylaxis-failure-with-tenofovir-disoproxil
#15
Julie Fox, Simon Collins
No abstract text is available yet for this article.
June 1, 2017: AIDS
https://www.readbyqxmd.com/read/28492392/predictors-of-estimated-glomerular-filtration-rate-progression-stabilization-or-improvement-after-chronic-renal-impairment-in-hiv-positive-individuals
#16
Lene Ryom, Amanda Mocroft, Ole Kirk, Peter Reiss, Michael Ross, Colette Smith, Olivier Moranne, Philippe Morlat, Christoph A Fux, Caroline Sabin, Andrew Phillips, Matthew Law, Jens D Lundgren
OBJECTIVES: The objectives of this analysis were to investigate predictors of progression, stabilization or improvement in estimated glomerular filtration rate (eGFR) after development of chronic renal impairment (CRI) in HIV-positive individuals. DESIGN: Prospective observational study. METHODS: The Data Collection on Adverse events of Anti-HIV Drugs (D:A:D) study participants progressing to CRI defined as confirmed, at least 3 months apart, and eGFR 70 ml/min per 1...
June 1, 2017: AIDS
https://www.readbyqxmd.com/read/28489856/randomized-trial-of-stopping-or-continuing-art-among-postpartum-women-with-pre-art-cd4-%C3%A2-400-cells-mm3
#17
Judith S Currier, Paula Britto, Risa M Hoffman, Sean Brummel, Gaerolwe Masheto, Esau Joao, Breno Santos, Linda Aurpibul, Marcelo Losso, Marie F Pierre, Adriana Weinberg, Devasena Gnanashanmugam, Nahida Chakhtoura, Karin Klingman, Renee Browning, Anne Coletti, Lynne Mofenson, David Shapiro, Jose Pilotto
BACKGROUND: Health benefits of postpartum antiretroviral therapy (ART) for human immunodeficiency virus (HIV) positive women with high CD4+ T-counts have not been assessed in randomized trials. METHODS: Asymptomatic, HIV-positive, non-breastfeeding women with pre-ART CD4+ T-cell counts ≥ 400 cells/mm3 started on ART during pregnancy were randomized up to 42 days after delivery to continue or discontinue ART. Lopinavir/ritonavir plus tenofovir/emtricitabine was the preferred ART regimen...
2017: PloS One
https://www.readbyqxmd.com/read/28484508/cohort-profile-the-complications-of-long-term-antiretroviral-therapy-study-in-uganda-coltart-a-prospective-clinical-cohort
#18
Billy Nsubuga Mayanja, Ivan Kasamba, Jonathan Levin, Ivan Namakoola, Patrick Kazooba, Jackson Were, Pontiano Kaleebu, Paula Munderi
BACKGROUND: Antiretroviral therapy (ART) improves the survival and quality of life of HIV-positive individuals, but the effects of long-term ART use do eventually manifest. The Complications of Long-Term Antiretroviral Therapy cohort study in Uganda (CoLTART) was established to investigate the metabolic and renal complications of long-term ART use among Ugandan adults. We describe the CoLTART study set-up, aims, objectives, study methods, and also report some preliminary cross-sectional study enrolment metabolic and renal complications data analysis results...
2017: AIDS Research and Therapy
https://www.readbyqxmd.com/read/28480762/steady-state-pharmacokinetics-of-tenofovir-disoproxil-fumarate-in-human-immunodeficiency-virus-infected-chinese-patients
#19
Xiaoli Du, Huijuan Kou, Qiang Fu, Yanling Li, Zhu Zhu, Taisheng Li
BACKGROUND: The pharmacokinetic (PK) profile of tenofovir disoproxil fumarate in Chinese adults infected with HIV is unknown. RESEARCH DESIGN AND METHODS: A pilot, prospective, open-label study was performed to investigate the steady-state PK profile of tenofovir disoproxil fumarate in 15 Chinese HIV-infected patients among whom eight patients were treated with 300 mg tenofovir disoproxil fumarate, 300 mg lamivudine and 400/100 mg lopinavir/ritonavir, and seven with 300 mg tenofovir disoproxil fumarate, 300 mg lamivudine and 400 mg nevirapine...
May 8, 2017: Expert Review of Clinical Pharmacology
https://www.readbyqxmd.com/read/28480227/influence-of-sex-gender-and-race-on-responses-to-raltegravir-combined-with-tenofovir-emtricitabine-in-treatment-naive-human-immunodeficiency-virus-1-infected-patients-pooled-analyses-of-the-startmrk-and-qdmrk-studies
#20
Kathleen Squires, Linda-Gail Bekker, Christine Katlama, Yazdan Yazdanpanah, Yan Zhou, Anthony J Rodgers, Mark J DiNubile, Peter A Sklar, Randi Y Leavitt, Hedy Teppler
BACKGROUND: Antiretroviral therapy in human immunodeficiency virus (HIV)-infected women and blacks merits particular scrutiny because these groups have been underrepresented in clinical trials. METHODS: To document the effects of raltegravir across sex and racial lines, we conducted a pooled subgroup analysis of the efficacy and safety of raltegravir 400 mg BID plus tenofovir-emtricitabine by sex (women vs men) and self-identified race (black vs non-black) using phase 3 studies in treatment-naive patients...
2017: Open Forum Infectious Diseases
keyword
keyword
2109
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"